PARP-1 Inhibitors
Items 1 to 10 of 26 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT-888 | 912445-05-7 | sc-202901 sc-202901A sc-202901B | 1 mg 5 mg 25 mg | $117.00 $173.00 $510.00 | 24 | |
ABT-888 is characterized by its selective inhibition of PARP-1, facilitated by its unique structural motifs that allow for specific interactions with the enzyme's catalytic domain. The compound's aromatic rings enhance π-π stacking interactions, promoting stability in the enzyme-inhibitor complex. Furthermore, its ability to modulate conformational dynamics within PARP-1 may influence substrate accessibility, thereby affecting the overall efficiency of DNA repair mechanisms. | ||||||
BYK204165 | 1104546-89-5 | sc-214642 sc-214642A | 5 mg 25 mg | $108.00 $446.00 | 2 | |
BYK204165 exhibits a distinctive mechanism of action as a PARP-1 inhibitor, primarily through its ability to form hydrogen bonds with key residues in the enzyme's active site. This interaction not only stabilizes the enzyme-inhibitor complex but also alters the enzyme's conformational landscape, potentially impacting its catalytic efficiency. Additionally, the compound's hydrophobic regions facilitate interactions with lipid membranes, influencing cellular uptake and distribution. | ||||||
Minocycline, Hydrochloride | 13614-98-7 | sc-203339 sc-203339A sc-203339B sc-203339C sc-203339D sc-203339E sc-203339F | 50 mg 250 mg 1 g 2.5 g 10 g 100 g 1 kg | $52.00 $171.00 $281.00 $634.00 $1259.00 $5836.00 $24980.00 | 36 | |
Minocycline, Hydrochloride demonstrates unique interactions with PARP-1 by engaging in π-π stacking and hydrophobic interactions, which enhance binding affinity. Its structural conformation allows for effective competition with NAD+ at the enzyme's active site, disrupting the repair of DNA single-strand breaks. The compound's amphipathic nature promotes membrane permeability, potentially affecting intracellular localization and bioavailability, thereby influencing its overall biochemical behavior. | ||||||
DPQ | 129075-73-6 | sc-202755 sc-202755A | 1 mg 5 mg | $66.00 $256.00 | 18 | |
DPQ exhibits distinctive interactions with PARP-1 through hydrogen bonding and electrostatic interactions, which facilitate its binding to the enzyme. Its rigid molecular structure allows for effective inhibition of PARP-1 activity by obstructing the enzyme's catalytic site, thereby interfering with the DNA damage response. Additionally, DPQ's lipophilic characteristics enhance its cellular uptake, potentially altering its distribution and interaction dynamics within biological systems. | ||||||
NU 1025 | 90417-38-2 | sc-203166 | 5 mg | $131.00 | 9 | |
NU 1025 demonstrates unique binding affinity for PARP-1, characterized by specific hydrophobic interactions and conformational adaptability. Its molecular design promotes a stable complex formation, effectively modulating the enzyme's activity. The compound's kinetic profile reveals a rapid association and slower dissociation, indicating a strong inhibitory effect. Furthermore, NU 1025's solubility properties enhance its interaction with cellular membranes, influencing its bioavailability and distribution within various environments. | ||||||
3-Methyl-5-AIQ hydrochloride | sc-220870 | 1 mg | $260.00 | |||
3-Methyl-5-AIQ hydrochloride exhibits a distinctive mechanism of action through its selective interaction with PARP-1, leveraging unique hydrogen bonding and electrostatic interactions. This compound's structural features facilitate a dynamic conformational shift, optimizing its binding efficiency. The reaction kinetics highlight a pronounced affinity, with a notable rate of complex formation that underscores its potential for sustained enzyme modulation. Additionally, its solubility characteristics enhance permeability across biological membranes, impacting its localization and interaction within cellular systems. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Niraparib inhibits PARP-1 and traps PARP-DNA complexes, preventing DNA repair and causing cancer cell death. | ||||||
PARP Inhibitor VIII, PJ34 | 344458-15-7 | sc-204161 sc-204161A | 1 mg 5 mg | $58.00 $142.00 | 20 | |
PARP Inhibitor VIII, PJ34, showcases a remarkable ability to disrupt the PARP-1 enzyme's catalytic activity through specific binding interactions. Its unique structural motifs allow for effective steric hindrance, preventing substrate access. The compound's rapid association and dissociation kinetics contribute to its transient yet impactful modulation of DNA repair pathways. Furthermore, its hydrophobic regions enhance membrane interaction, influencing cellular uptake and distribution dynamics. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide acts as a potent modulator of PARP-1 by engaging in specific non-covalent interactions that stabilize the enzyme's inactive conformation. Its unique nitrogenous structure facilitates hydrogen bonding with key residues, effectively altering the enzyme's active site dynamics. This compound exhibits a distinctive ability to influence the conformational landscape of PARP-1, thereby impacting its role in cellular stress responses and DNA damage signaling pathways. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib functions as a selective inhibitor of PARP-1, characterized by its ability to disrupt the enzyme's catalytic activity through competitive binding at the NAD+ site. Its unique structural features allow for specific interactions with the enzyme's active site, leading to conformational changes that hinder DNA repair mechanisms. This compound exhibits a remarkable affinity for PARP-1, influencing the enzyme's kinetics and altering cellular responses to genotoxic stress. | ||||||